Drugmakers cut antibiotics R&D as superbugs take hold

03/19/2013 | Reuters

Despite concerns about drug-resistant bacteria, few drugmakers are developing new antibiotics and some have trimmed their antibiotics research spending. Regulatory hurdles and relatively low market pricing make antibiotics development unattractive. Public-private partnerships might shift the playing field, and more research sharing could boost innovation, GlaxoSmithKline CEO Andrew Witty said.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA